Implantica achieves regulatory authorisation for RefluxStop™ in New Zealand
Implantica AG (publ) today announces that RefluxStop™ has been granted marketing authorisation from the New Zealand Medicines and Medical Devices Safety Authority (Medsafe).RefluxStop™ is a clinically proven treatment for acid reflux that treats the cause of the disease, allowing a natural physiological function of the lower esophageal sphincter (LES) without affecting the food passageway. Peter Forsell, CEO of Implantica said, “Achieving market authorisation in New Zealand is another step in our regulatory strategy. We are looking forward to commercializing RefluxStop™ in New Zealand.